Taken together, our immunohistochemical findings suggest (1) that SgII is widespread in malignant melanomas and their metastases, supporting the hypothesis that upregulation of SgII may be relevant for their pathogenesis in vivo, and (2) that Dsg2 is not junction bound but atypically distributed in most melanomas and melanoma metastases. Here, SCG2 is linked to melanoma.